Diabetic ketoacidosis in a patient: diagnostic error and poor praxis
DOI:
https://doi.org/10.32818/reccmi.a4n3a13Keywords:
type 1 diabetes mellitus, diabetic ketoacidosis, ketosis, type 2 sodium-glucose transporter inhibitorsAbstract
Occasionally, type 2 diabetes mellitus (T2DM) is diagnosed in patients with type 1 diabetes mellitus (T1DM), especially in obese subjects without diabetic ketoacidosis (DKA). This can be serious, among other things, because the type 2 sodium-glucose transporter inhibitors used in T2DM are associated with euglycemic DKA. We present the case of a 42-year-old male with 13-year-old T2DM who presented severe DKA due to dapagliflozin, as well as a severe intrahospital ketosis due to omission of subcutaneous insulin doses. Finally, the diagnosis of T1DM was made.
Downloads
Metrics
References
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047-1053. doi: https://doi.org/10.2337/diacare.27.5.1047.
Ruíz-Ramos M, Escolar-Pujolar A, Mayoral-Sánchez E, Corral-San Laureano F, Fernández-Fernández I. La diabetes mellitus en España: mortalidad, prevalencia, incidencia, costes económicos y desigualdades. Gac Sanit. 2006; 20(Supl 1): 15-24. doi: https://doi.org/10.1157/13086022.
Merger SR, Leslie RD, Boehm BO. The broad clinical phenotype of type 1 diabetes at presentation. Diabet Med. 2013; 30(2): 170-178. doi: https://doi.org/10.1111/dme.12048.
Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism. 2016; 65(4): 507-521. doi: https://doi.org/10.1016/j.metabol.2015.12.007.
Misaghian-Xanthos N, Shariff AI, Mekala K, Fearrington LR, Setji TL, Aloi JA et al. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis: a case series from three academic institutions. Diabetes Care. 2017; 40(6): e65-e66. doi: https://doi.org/10.2337/dc16-2591.
Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoaci- dosis. J Clin Endocrinol Metab. 2015; 100(8): 2849-2852. doi: https://doi.org/10.1210/jc.2015-1884.
European Medicines Agency. EMA confirms recommendations to minimize ketoacidosis risk with SGLT2 inhibitors for diabetes. Healthcare professionals should be aware of possible atypical cases. European Medicines Agency, 2016. Accesible en: https://www.ema.europa.eu/en/news/ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes (último acceso 19-11-2019).
Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017; 5(2): 2324709617710040. doi: https://doi.org/10.1177/2324709617710040.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Óscar Moreno-Domínguez, Diego Meneses-González, Noemí González-Pérez de Villar, Lucrecia Herranz-de la Morena
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
